GNOM:SW:SW-Global X Genomics & Biotechnology UCITS ETF USD Acc CHF (CHF)

ETF | Others |

Last Closing

USD 6.663

Change

+0.02 (+0.35)%

Market Cap

USD 6.06M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

-0.06 (-0.46%)

USD 1,244,681.59B
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

-0.06 (-0.46%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

-0.07 (-0.33%)

USD 226,274.25B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

-0.07 (-0.33%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.06 (-0.22%)

USD 226,274.21B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.06 (-0.22%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

-10.00 (-0.12%)

USD 134,034.93B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

-10.00 (-0.12%)

USD 134,034.93B

ETFs Containing GNOM:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.49% 5% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.49% 5% F 9% A-
Trailing 12 Months  
Capital Gain 2.78% 13% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.78% 13% F 17% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.20% N/A N/A 8% B-
Dividend Return -5.20% N/A N/A 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.67% N/A N/A 54% F
Risk Adjusted Return -67.73% N/A N/A 5% F
Market Capitalization 6.06M 5% F 4% F

Annual Financials (CHF)

Quarterly Financials (CHF)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.